According to Insidermedia.com, Clinigen has nailed down £50 million as the U.K.-based specialty pharma group is expected to hit the AIM market next week with a market value of £135 million. The company, which sells the HIV med Foscavir, could be the first biopharma IPO out of the U.K. since the drug developer e-Therapeutics went public in 2007, Bloomberg editor Kristen Hallam noted on Twitter today. Article